Related references
Note: Only part of the references are listed.Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
Jesus Rodriguez-Bano et al.
CLINICAL MICROBIOLOGY AND INFECTION (2021)
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial
Olivier Hermine et al.
JAMA INTERNAL MEDICINE (2021)
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia A Randomized Clinical Trial
Carlo Salvarani et al.
JAMA INTERNAL MEDICINE (2021)
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Zunyou Wu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China
Dawei Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial
Jesus Villar et al.
LANCET RESPIRATORY MEDICINE (2020)
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
Yang Cao et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab
Austin R. Morrison et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
Chaomin Wu et al.
JAMA INTERNAL MEDICINE (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
Emanuel Della-Torre et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study
Sofia Ramiro et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) A Review
W. Joost Wiersinga et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients
Lorenzo M. Canziani et al.
JOURNAL OF AUTOIMMUNITY (2020)
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 The GRECCO-19 Randomized Clinical Trial
Spyridon G. Deftereos et al.
JAMA NETWORK OPEN (2020)
Safety and efficacy of anti-i16-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis
Roberto Rossotti et al.
JOURNAL OF INFECTION (2020)
Factors associated with COVID-19-related death using OpenSAFELY
Elizabeth J. Williamson et al.
NATURE (2020)
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis
Jonathan A. C. Sterne et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
John H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
Giulio Cavalli et al.
LANCET RHEUMATOLOGY (2020)
Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome
Chelsea Kotch et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2019)
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
Robert Q. Le et al.
ONCOLOGIST (2018)
Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis
Cem Gabay et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Share Paper
